RioTech has embarked
on a strategy for formation of partnerships with focused HCV companies either in
the category of big Pharma or large biotech sectors. Based on the
potential scope of interest, licensing or other broader alliance relationships
are both being actively pursued by RioTech. Given the wide industry
interest in the Interferon field, discussions are already underway particularly
on the subject of RioTech’s more advanced program.
